Generics in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Indonesia
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Indonesia
Leading company profiles reveal details of key generics market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Indonesia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons to Buy
What was the size of the Indonesia generics market by value in 2016?
What will be the size of the Indonesia generics market in 2021?
What factors are affecting the strength of competition in the Indonesia generics market?
How has the market performed over the last five years?
How large is Indonesia's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Indonesian generics market is expected to generate total revenues of $911m in 2016, representing a compound annual growth rate (CAGR) of 15.9% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 2.1% between 2012 and 2016, to reach a total of 47.5% of total pharma volume in 2016.
The Indonesian market should continue to see strong growth as the country's first compulsory national health insurance system, which aims to make basic care available to every citizen by 2019, was launched in January 2014.
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
PT Kalbe Farma Tbk
PT Indofarma (Persero), Tbk
PT Sanbe Farma
PT Soho Global Health
Related MarketLine research
Figure 1: Indonesia generics market value: $ billion, 2012-16(e)
Figure 2: Indonesia generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Indonesia generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Indonesia generics market value forecast: $ billion, 2016-21
Figure 5: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Indonesia, 2016
Figure 7: Drivers of buyer power in the generics market in Indonesia, 2016
Figure 8: Drivers of supplier power in the generics market in Indonesia, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Indonesia, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Indonesia, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Indonesia, 2016
Figure 12: PT Kalbe Farma Tbk: revenues & profitability
Figure 13: PT Kalbe Farma Tbk: assets & liabilities
Figure 14: PT Indofarma (Persero), Tbk: revenues & profitability
Table 1: Indonesia generics market value: $ billion, 2012-16(e)
Table 2: Indonesia generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Indonesia generics market geography segmentation: $ billion, 2016(e)
Table 4: Indonesia generics market value forecast: $ billion, 2016-21
Table 5: Indonesia generics market volume forecast: % of total pharma volume, 2016-21
Table 6: PT Kalbe Farma Tbk: key facts
Table 7: PT Kalbe Farma Tbk: key financials ($)
Table 8: PT Kalbe Farma Tbk: key financials (IDR)
Table 9: PT Kalbe Farma Tbk: key financial ratios
Table 10: PT Indofarma (Persero), Tbk: key facts
Table 11: PT Indofarma (Persero), Tbk: key financials ($)
Table 12: PT Indofarma (Persero), Tbk: key financials (IDR)
Table 13: PT Indofarma (Persero), Tbk: key financial ratios
Table 14: PT Sanbe Farma: key facts
Table 15: PT Soho Global Health: key facts
Table 16: Indonesia size of population (million), 2012-16
Table 17: Indonesia gdp (constant 2005 prices, $ billion), 2012-16
Table 18: Indonesia gdp (current prices, $ billion), 2012-16
Table 19: Indonesia inflation, 2012-16
Table 20: Indonesia consumer price index (absolute), 2012-16
Table 21: Indonesia exchange rate, 2012-16
Single User License:
Corporate User License:
PT Kalbe Farma Tbk, PT Indofarma (Persero), Tbk, PT Sanbe Farma, PT Soho Global Health
Generics, MarketLine, Indonesia
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"